Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2006 by McGill University Health Center.
Recruitment status was:  Recruiting
Merck Frosst Canada Ltd.
Information provided by:
McGill University Health Center Identifier:
First received: June 27, 2006
Last updated: April 11, 2007
Last verified: January 2006
To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture

Condition Intervention Phase
Drug: Alendronate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Six Month Double-Blind, Placebo-Controlled Trial Followed by Six Month Open-Label Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

Resource links provided by NLM:

Further study details as provided by McGill University Health Center:

Estimated Enrollment: 10
Study Start Date: January 2003
Estimated Study Completion Date: April 2007

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Male and Female aged > 55 Low trauma hip fracture up to 90 days Be willing to submit to periodic bone mineral density radiographic studies of the spine & 24 hr urine collection Written informed consent

Exclusion Criteria:

  • Disorders known to affect bone metabolism Not taking bisphosphonates within last 6 months Drugs known to interfere with calcium metabolism within the lats 6 months prior to hip fracture serum calcium> 2.65 mmol/L Treatment with any investigational drug within the last 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00346190

Contact: Richard Kremer, MD PhD 514-934-1934 ext 32857
Contact: Giselle Charrette, RN CONc 514-934-1934 ext 35718

Canada, Quebec
Mcgill University Health center Recruiting
Montreal, Quebec, Canada, H3A 1A1
Contact: Richard Kremer, MD PhD    514-934-1934 ext 32857      
Principal Investigator: Richard Kremer, MD PhD FRCP(c)         
Sponsors and Collaborators
McGill University Health Center
Merck Frosst Canada Ltd.
Principal Investigator: Richard Kremer, MD PhD McGill University Health Center
  More Information Identifier: NCT00346190     History of Changes
Other Study ID Numbers: CA-16
Study First Received: June 27, 2006
Last Updated: April 11, 2007

Additional relevant MeSH terms:
Hip Fractures
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Femoral Fractures
Fractures, Bone
Wounds and Injuries
Hip Injuries
Leg Injuries
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on April 28, 2017